MDxHealth Signs Research Collaboration With University Of Oxford To Assess The Correlation Of The GPS Test With Prostate Cancer Progression Following Treatment For Localized Prostate Cancer
Portfolio Pulse from Benzinga Newsdesk
MDxHealth SA (NASDAQ/Euronext: MDXH) has announced a research collaboration with the University of Oxford to investigate the correlation between the Genomic Prostate Score (GPS) test and prostate cancer progression following treatment for localized prostate cancer. The collaboration will involve GPS testing on patient samples from the Prostate Mechanisms of Progression and Treatment (ProMPT) cohort.
September 26, 2023 | 8:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MDxHealth's collaboration with the University of Oxford could potentially enhance the company's reputation in the field of precision diagnostics and may lead to advancements in prostate cancer treatment.
The collaboration with a prestigious institution like the University of Oxford could enhance MDxHealth's credibility in the field of precision diagnostics. If the research yields positive results, it could lead to advancements in prostate cancer treatment, potentially increasing the demand for MDxHealth's Genomic Prostate Score test and positively impacting the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100